Novo Nordisk (NVO) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Novo Nordisk AS (NVO) Prix de l'Action, Cotation, Actualités et Historique

NVONYSE

Trade with Public

Trade with Public

$38.82

-0.40-1.02%

Dern. MÀJ: Oct 16, 7:59 PM

$38.73

-0.49-1.25%

AperçuActualités Prévisions de résultats Objectifs de cours Données financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

$39.33

Clôture

$38.82

Volume / Moy.

10.82M / 12.61M

Fourchette Journalière

$38.73 - $38.73

Plage 52 Sem.

35.12 - 64.16

Capitalisation Boursière

$168.23B

Ratio P/E

9.55

Rendement des Dividendes

4.58%

Échange

NYSE

RSI

33

Intérêt à Découvert

1%

Jours pour Couvrir

1.74

Actualités Récentes de Novo Nordisk A/S

QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom

REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.

Chandrima Sanyal

Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’

PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its authority under federal law.

Mohd Haider

FDA Delays Regulatory Decision On Novo Nordisk Hemophilia Drug

FDA extends review for Novo Nordisk's denecimig over manufacturing remediation. Financial outlook remains unchanged with 2027 launch goal.

Vandana Singh

Anthropic Commits $100 Million Behind AI Talent Push, Plans to Train 10,000 Engineers by 2027 as IPO Looms

Anthropic launches a $100 million academy to train 10,000 AI engineers by 2027 as demand for AI talent surges.

Mohd Haider

Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data

Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.

Vandana Singh

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

131.88B

Flux de Trésorerie d'Investissement (TTM)

-83.54B

Flux de Trésorerie de Financement (TTM)

-22.24B

Flux de Trésorerie Libre (TTM)

47.79B

Dépenses en Capital (TTM)

-84.09B

Variation Nette de la Trésorerie (TTM)

26.10B

Tendances et prévisions des analystes

1

sept.

1

oct.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

3.4

Conserver

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$192.79B

Ratio P/E (TTM)

9.55

Ratio P/E (FWD)

12.03

Ratio PEG (TTM)

4.39

Ratio P/S (TTM)

3.55

Ratio P/B (TTM)

5.69

Rendement des Bénéfices % (TTM)

10.47%

Rendement des Bénéfices % (FWD)

8.31%

EV / EBITDA (TTM)

7.46

Prix / EBITDA (TTM)

6.75

Prix / Flux de Trésorerie Libre (TTM)

37.69

Valeur Comptable / Action

$6.89

Dette Entreprise

Dette Totale

$140.13B

Dette à Long Terme

$121.79B

Émission de Dette à Long Terme (TTM)

$66.08B

Remboursement de la Dette à Long Terme (TTM)

-$29.64B

Trésorerie Totale

$44.48B

Dette sur Capitaux Propres

0.63

Émission de Dette (TTM)

$36.44B

Remboursement de la Dette (TTM)

-$29.64B